<tt id="vj5km"><sup id="vj5km"><nobr id="vj5km"></nobr></sup></tt>
  • <input id="vj5km"><big id="vj5km"><p id="vj5km"></p></big></input>
    <i id="vj5km"></i>
    <input id="vj5km"><table id="vj5km"></table></input>
  • <source id="vj5km"><big id="vj5km"><acronym id="vj5km"></acronym></big></source>
    <video id="vj5km"></video>
    <i id="vj5km"><bdo id="vj5km"></bdo></i>

    <tt id="vj5km"><bdo id="vj5km"><var id="vj5km"></var></bdo></tt>
    <video id="vj5km"><ins id="vj5km"><big id="vj5km"></big></ins></video>

    <video id="vj5km"><ins id="vj5km"></ins></video>


    International Market

    Hansoh actively implements the internationalization strategy and has been committed itself to human being’s health with its professional expertise, through sales of internationally certified APIs and finished-dose pharmaceutical products to  the U.S. and other countries, and  international multi-center clinical trials for innovative drugs.   

    Market Internationalization 

    Multiple finished-dose pharmaceutical products and APIs are sold to the global market. 

    R&D Internationalization 

    Global multi-center clinical trials are under way simultaneously in the U.S. and China for HS-10296, a Category 1.1 innovative oncology drug, amid efforts for global expansion of innovative drugs.